 Aware Recovery Care now offers an in-home detox program called In-Home Withdrawal Management (IHWM) to Indiana residents. The program allows clients who meet eligibility criteria to safely and effectively detox in the comfort of their homes, avoiding pathogens that they may be exposed to in a facility and averting the trauma of leaving loved ones for essential treatment of the disease. Treatment is personalized to each client and his or her individual needs so the participant can be comfortable and safe during detox. Aware plans to extend its in-home detox program to additional states in the near future. About 88% of patients who received In-Home Withdrawal Management remained abstinent for at least 90 days after.
 The American Medical Association (AMA) is continuing to pressure regulators, legislators and manufacturers to expand the availability of naloxone to help end the drug-overdose epidemic. This includes removing naloxone’s prescription status, making it available over the counter (OTC). Part of the AMA’s efforts include writing Rahul Gupta, MD, director of the White House Office of National Drug Control Policy (ONDCP), to encourage him to make naloxone available over the counter. The AMA has also urged naloxone manufacturers to submit applications for naloxone OTC status to the U.S. Food and Drug Administration. Naloxone is an important life-saving tool that the public can use for preventing drug overdose deaths. Making it more accessible will only benefit our society. The AMA and Manatt have released a toolkit to guide states on removing barriers to evidence-based patient care.
 Please visit the Indiana Drug Overdose Dashboard, where you will find data from 2017 up to provisional data for 2021. In this dashboard, you will find data regarding opioid prescriptions, hospital discharges, and drug-related deaths.
|
